A carregar...
Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy
Janus kinase (JAK) enzymes are involved in cell signaling pathways activated by various cytokines dysregulated in allergy. The objective of this study was to determine whether the novel JAK inhibitor oclacitinib could reduce the activity of cytokines implicated in canine allergic skin disease. Using...
Na minha lista:
| Publicado no: | J Vet Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BlackWell Publishing Ltd
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4265276/ https://ncbi.nlm.nih.gov/pubmed/24495176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvp.12101 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|